Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study

Table 2 Incidence and risk of end-stage renal disease in patients with inflammatory bowel diseases

	Total No. (n)	ESRD cases (n)	Person-years	ESRD incidence (per 1000 person-years)	Crude HR (95%CI)	P value	Model 11 HR (95%CI)	P value	Model 22 HR (95%CI)	P value	Model 33 HR (95%CI)	P value
Total IBD						0.009		0.009		< 0.001		< 0.001
Non-IBD control	116436	166	568575	0.29	1 (reference)		1 (reference)		1 (reference)		1 (reference)
IBD cohort	38812	79	189245	0.42	1.43 (1.09-1.87)		1.43 (1.09-1.87)		1.67 (1.27-2.18)		3.03 (1.77-5.20)
IBD subgroup						0.013		0.004		< 0.001		< 0.001
Non-IBD control	116436	166	568575	0.29	1 (reference)		1 (reference)		1 (reference)		1 (reference)
Incident IBD group	16606	32	65646	0.49	1.71 (1.17-2.50)		1.89 (1.29-2.73)		1.72 (1.17-2.52)		3.06 (1.71-5.47)
Prevalent IBD group	22206	47	123600	0.38	1.29 (0.93-1.78)		1.23 (0.89-1.70)		1.63 (1.18-2.27		3.01 (1.67-5.43)

¹Model 1: adjusted for age and sex;

²Model 2: adjusted for model 1 + place of residence, income, diabetes mellitus, hypertension, dyslipidemia, congestive heart failure, ischemic heart disease, and gout and/or hyperuricemia;

³Model 3: adjusted for model 2 + medication use (5-aminosalicylic acid, corticosteroids, immunomodulators, and anti-tumor necrosis factor -α agents). CI: Confidence interval; ESRD: End-stage renal disease; HR: Hazard ratio; IBD: Inflammatory bowel disease; No: Number.